Phase II Trial of HRS-7450 Injection for Acute Ischemic Stroke Initiated by Fujian Shengdi
Fujian Shengdi Pharmaceutical has initiated Phase II clinical trial for HRS-7450 Injection targeting Acute Ischemic Stroke.
Therapeutic Area
Therapeutic area intelligence for Acute Ischemic Stroke with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.